Skip to content
Open access

Therapeutic potential of nasal kisspeptin-54 for reducing α-synuclein accumulation and restoring hippocampal synaptic plasticity in a 6-hydroxydopamine-induced rat model of Parkinson’s disease

Jun 2026 · Turkish Journal of Medical Sciences · Vol 56, pp. 1320 - 1331 · 0 citations · 54 references
Medicine

TL;DR

It is indicated that nasal KP-54 administration exerts neurorestorative effects in a 6-OHDA rat model of PD by preserving dopaminergic neurons, improving synaptic function, and attenuating pathological α-syn aggregation.

Abstract

Background/aim Parkinson’s disease (PD) is characterized by progressive degeneration of dopaminergic neurons and pathological aggregation of α-synuclein (α-syn), leading to significant motor and cognitive impairments. Kisspeptin-54 (KP-54), a neuropeptide primarily involved in reproductive regulation, has recently been implicated in neurorestorative processes, with emerging evidence suggesting beneficial effects on locomotor activity and cognitive function. However, its therapeutic potential in PD has not yet been fully investigated. This study aimed to evaluate the therapeutic efficacy of chronic nasal KP-54 administration in a 6-hydroxydopamine (6-OHDA) rat model of PD, focusing on motor and cognitive outcomes, hippocampal synaptic plasticity, and α-syn pathology. Materials and methods Adult Sprague–Dawley rats underwent unilateral 6-OHDA injections into the medial forebrain bundle to induce dopaminergic degeneration. Beginning 3 weeks after lesion induction, animals received daily nasal KP-54 or vehicle treatment for an additional 3 weeks. Motor performance was assessed using the catalepsy, beam balance, and open field tests, whereas cognitive function was evaluated using the Y-maze and object location test. Baseline assessments were conducted on day 0 prior to lesion formation. Electrophysiological recordings obtained from the hippocampal CA1 region were used to assess synaptic plasticity. Dopaminergic neuron survival and α-syn accumulation in the substantia nigra and hippocampus were quantified by immunofluorescence analysis. Results Chronic nasal KP-54 significantly ameliorated motor and cognitive deficits induced by 6-OHDA. KP-54 restored hippocampal synaptic plasticity, enhanced the survival of tyrosine hydroxylase-positive dopaminergic neurons, and reduced α-syn accumulation in both the substantia nigra and hippocampus. Conclusion The findings indicate that nasal KP-54 administration exerts neurorestorative effects in a 6-OHDA rat model of PD by preserving dopaminergic neurons, improving synaptic function, and attenuating pathological α-syn aggregation. These results position KP-54 as a promising candidate for disease-modifying therapy in Parkinson’s disease.

Read PDF

Similar papers

Open access Sep 2026

Oral sodium butyrate alleviates motor deficits and dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson’s disease rat model

This model indicates the therapeutic potential of oral NaB and provides a translational framework for investigating the mechanisms of NaB therapy in PD and associated neurological disorders and alleviated motor and non-motor deficits in rats with 6-OHDA-induced PD.

Shun-Tai Yang, Yang-Ching Chen, Tzu-Jen Kao et al. · 0 citations
Aug 2026

Astragalin confers coordinated neuroprotection in Parkinson's disease models through modulation of neurotrophic, anti-inflammatory, and synuclein-related pathways.

The natural flavonoid Astragalin concurrently addresses three core pathological processes in PD, namely dopaminergic neuron degeneration, α-synucleinopathy, and neuroinflammation, through coordinated modulation of interconnected molecular pathways.

Jun Wang, Jie-Yu He, Qin Huang et al. · 0 citations
Aug 2026

Cobrotoxin suppresses TLR4-NF-κB/STAT1 signaling to mitigate glia-mediated neuroinflammation and motor deficits in Parkinson's disease.

Chronic neuroinflammation is implicated in the pathogenesis of Parkinson's disease (PD), contributing to progressive dopaminergic neuron loss. Cobrotoxin (CoTX), a short-chain α-neurotoxin isolated from Naja atra venom, exerts anti-inflammatory and analgesic effects in several inflammation-related disease models. Howev...

Chun-Ze Yu, Shuyang Ma, Yuzhihan Cao et al. · 0 citations
Aug 2026

Neuroprotective effects of myricetin against rotenone-ınduced parkinsonian neurotoxicity: a multidimensional analysis in rats

MyR attenuated RTN-induced neurotoxicity and was associated with improved behavioral performance, reduced OS, and preservation of neuronal morphology, which support the protective potential of MYR against RTN-induced neurotoxicity exhibiting Parkinsonian-like features.

O. Ozhan, Zehranur Erikci, A. Yıldız et al. · 0 citations
Review Open access Aug 2026

Neuroprotective Potential of Semaglutide in Parkinson’s Disease: Mechanisms, Preclinical Evidence, and Clinical Perspectives

A narrative review evaluates the therapeutic potential of semaglutide in PD, focusing on its molecular mechanisms and preclinical and emerging clinical evidence, and suggests that semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in neuronal and glial cells, reducing microglial activation, neuro...

Dipesh Kumar, Renuka Sahu, Naveen Kumar et al. · 0 citations
Open access Aug 2026

PT320, a GLP-1 receptor agonist, mitigates nucleus accumbens–associated depression- and anxiety-like behaviors in MitoPark mice of Parkinson's disease

By restoring neurotrophic signaling and dopaminergic function, PT320 represents a promising therapeutic strategy for PD-related anxiety and depression by restoring neurotrophic signaling and dopaminergic function in the nucleus accumbens.

Kuan-Yin Tseng, Tung-Tai Kuo, P. Chang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.